Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: Results of a Japanese phase II clinical study

International Journal of Hematology

Volumn 80, Issue 3, 2004, Pages 261-266

  Morishima, Yasuo ^a   Ogura, Michinori ^a   Nishimura, Miki ^b   Yazaki, Fumiharu ^c   Bessho, Masami ^c   Mizoguchi, Hideaki ^d   Chiba, Shigeru ^e   Hirai, Hisamaru ^e   Tauchi, Tetsuzo ^f   Urabe, Akio ^g   Takahashi, Masatomo ^h   Ohnishi, Kazunori ⁱ   Yokozawa, Toshiya ^j   Emi, Nobuhiko ^j   Hirano, Masami ^k   Shimazaki, Chihiro ^l   Nakao, Shinji ^m   Kawai, Yasukazu ⁿ   Fujimoto, Masahiro ^o   Taguchi, Hirokuni ^p   Jinnai, Itsuro ^q   Ohno, Ryuzo ^a   more..

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^f TOKYO MEDICAL UNIVERSITY   (Japan)

^g Kanto Teishin Hospital   (Japan)

^h ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^m KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

ⁿ UNIVERSITY OF FUKUI   (Japan)

^o KANSAI MEDICAL UNIVERSITY   (Japan)

^p KOCHI UNIVERSITY   (Japan)

^q NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

more..

Author keywords

Chronic myeloid leukemia; Imatinib mesylate; Phase II clinical study

Indexed keywords

IMATINIB;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EYELID EDEMA; FACE EDEMA; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; JAPAN; LEUKOPENIA; MALE; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; RASH; TASTE DISORDER; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; FEMALE; HUMANS; JAPAN; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 20844463222     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.04074     Document Type: Article

References (19)

1. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-293.
2. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36:93-99.
3. Sattler M, Griffin JD. Mechanisms of transformation by BCR/ABL oncogene. Int J Hematol. 2001;73:278-291.
4. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature. 1985;315:550-554.
5. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst. 1997;89:1616-1620.
6. Ohnishi K, Ohno R, Tomonaga M, et al. A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood. 1995;86:906-916.
7. Hansen JA, Gooley T, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962-968.
8. Kodera Y, Morishima Y, Kato S, et al. Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia. Bone Marrow Transplant. 1999;24:995-1003.
9. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-560.
10. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997;90:4947-4952.
11. Druker BJ, Talpatz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
12. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
13. Kantarjian H, Sawyer C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
14. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873-2878.
15. Kaneta Y, Kagami Y, Katagiri T, et al. Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis. Jpn J Cancer Res. 2002;93:849-856.
16. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Administration of G-CSF (filgrastim, Neupogen) for imatinib mesylate (Gleevec)-induced neutropenia in chronic phase chronic myeloid leukemia (CML) patients (pts) is safe and facilitates the achievement of cytogenetic responses [abstract]. Blood. 2003;102:907a. Abstract 3374.
17. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
18. Kantarijan HM, Schiffer CA, Sawyer CL, et al. Imatinib (Gleevec) maintains favorable long-term outcome in chronic-phase chronic myeloid leukemia (CML) for patients failing interferon-alpha (IFN): follow up of a phase II study [abstract]. Blood. 2003;102:905a. Abstract 3368.
19. Marin D, Marktel S, Szydlo R, et al. Survival of patients with chronic-phase chronic myeloid leukemia on imatinib after failure on interferon alfa. Lancet. 2003;362:617-619.